Blockade of the serotonergic system counteracts the dizocilpine-induced changes in dopaminergic function

Behavioural Pharmacology

Volumn 11, Issue 1, 2000, Pages 29-36

  Dall'Olio, Rossella ^a   Gandolfi, O ^a   Gaggi, R ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

8 OH DPAT; Apomorphine; Dizocilpine; DOI; Ketanserin; Methysergide; Quinpirole; Rat; SKF 38393

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; APOMORPHINE; DIZOCILPINE; DOPAMINE RECEPTOR; KETANSERIN; METHYSERGIDE; QUINPIROLE; SEROTONIN RECEPTOR;

AMINO ACID DEFICIENCY; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOPAMINE RECEPTOR BLOCKING; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; HYPERACTIVITY; INHIBITION KINETICS; MALE; MOTOR ACTIVITY; NONHUMAN; RAT; RECEPTOR BLOCKING; SEROTONINERGIC SYSTEM;

EID: 0033999025     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200002000-00003     Document Type: Article

References (29)

1. Carlsson M, Carlsson A (1990). Interaction between glutamatergic and monoaminergic systems within the basal ganglia - implication for schizophrenia and Parkinson's disease. Trends NeuroSci 13:272-276.
2. Carlsson A, Hansson LO, Waters N, Carlsson ML (1997). Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61:75-94.
3. Chapman CD, Gazzara RA, Howard SG (1990). Effects of phencyclidine on extracellular levels of dopamine, dihydrophenylacetic acid and homovanillic acid in conscious and anesthetized rats. Neuropharmacology 29:319-325.
4. Dall'Olio R, Gandolfi O, Montanaro N (1992). Effect of chronic treatment with dizocilpine (MK 801) on the behavioral response to dopamine receptor agonists in the rat. Psychopharmacology 107:591-594.
5. Dall'Olio R, Rimondini R, Gandolfi O (1995). The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 118:310-315.
6. 2 mediated behaviors in intact rats. Psychopharmacology 123:187-190.
7. Dall'Olio R, Gaggi R, Bonfante V, Gandolfi O (1999). The noncompetitive NMDA receptor blocker dizocilpine potentiates serotonergic function. Behav Pharmacol 10:63-71.
8. Dawbarn D, Pycock CJ (1981). Motor effects following application of putative excitatory amino acid antagonists to the region of the mesencephalic dopamine cell bodies in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 318:100-104.
9. Farley I, Shannak K, Hornykiewicz D (1980). Brain monoamine changes in chronic paranoid schizophrenia and their possible relation to increased dopamine receptor sensitivity. In: Receptor for Neurotransmitters and Peptide Hormones. Pepeu G, Kuhar M, Enna SJ (editors). New York: Raven Press, pp. 427-433.
10. 2 receptors. Eur J Pharmacol 255:203-213.
11. Glennon RA (1987). Central serotonin receptors as targets for drug research. J Med Chem 30:1-12.
12. Hjörth SA, Carlsson P, Lindberg P, Sanchez D, Wikstrom H, Arvidsson LE et al. (1982). 8-Hydroxy-2-(di-n-propylamino) tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity. J Neural Trans 55:169-188.
13. Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, Kleinman JE (1993). Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8:315-336.
14. Kelland MD, Freeman AS, Chiodo LA (1990). Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253:803-811.
15. Kim JS, Kornhuber HH, Schmid-Burgk W, Holzmuller B (1980). Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci Lett 20:379-382.
16. Lejeune F, Gobert A, Rivet JM, Millan MJ (1994). Blockade of transmission at NMDA receptors facilities the electrical and synthetic activity of ascending serotonergic neurones. Brain Res 656:427-431.
17. 2 receptors. Life Sci 28:1015-1022.
18. Löscher W, Annies R, Hönack D (1993). Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neural activity and behavioural effects in rats. Enr J Pharmacol 242:263-274.
19. 2-mediated behavior in the 6-hydroxydopamine model of turning relationship with c-fos expression. J Pharmacol Exp Ther 260:402-408.
20. Murray TF, Horita S (1979). Phencyclidine-induced stereotyped behavior in rats: dose-response effects and antagonism by neuroleptics. Life Sci 24:2217-2226.
21. 1 receptor blockade on MK-801 induced hyperlocomotion in rats. Psychopharmacology 111:427-434.
22. Peroutka SJ, Snyder SH (1980). Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 210:88-90.
23. 2A receptors in antipsychotic activity. Life Sci 56:2209-2222.
24. 1 receptor. Eur J Pharmacol 157:173-181.
25. Snyder SH (1988). Psychotogenic drugs as model of schizophrenia. Neuropsychopharmacology 1:197-199.
26. 3 receptor antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 163:115-118.
27. 2 receptor-dependent locomotion by glutamate antagonists in reserpine-treated mice. Eur J Pharmacol 250:239-246.
28. 2 dopamine agonists in reserpine-treated mice. Psychopharmacology 114:469-476.
29. Winblad B, Bucht G, Gottfries CG, Roos BE (1979). Monoamines and monoamine metabolites in brain from demented schizophrenics. Acta Psychiatr Scand 60:17-28.